Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiorphan is a potent small molecule inhibitor of membrane metalloendopeptidase (enkephalinase, also known as neprilysin). It was the first synthetic enkephalinase inhibitor developed and displays antinociceptive activity after systemic administration. Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms. It also inhibits angiotensin-converting enzyme to a lesser extent. Thiorphan has been shown to reduce castor oil-induced diarrhea in animal models when administered intravenously but not intracerebroventricularly. In clinical use, thiorphan is the active metabolite of racecadotril (acetorphan), an antidiarrheal medication that acts by inhibiting enkephalinases in the gut to reduce pathological secretion without affecting gastrointestinal motility[1][2][4][5][6][7][10]. Experimental studies suggest neuroprotective effects against excitotoxic brain injury[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiorphan.